Hospital Universitari General De Catalunya
- Address
- lock Available on a paid plan
Hospital Universitari General De Catalunya - Advanced Clinical Research Center
Hospital Universitari General De Catalunya is a distinguished clinical research institution conducting comprehensive trials across multiple therapeutic areas. The center demonstrates particular expertise in neurodegenerative diseases, oncology, and reproductive medicine, participating in pivotal international studies that advance medical knowledge and patient care.
- Alzheimer's Disease and Parkinson's Disease: Leading Phase 2 and 3 trials investigating novel therapeutics including anti-tau antibodies, alpha-synuclein targeting agents, and GLP-1 receptor agonists for cognitive and motor symptom management
- Breast Cancer Research: Conducting advanced studies in HER2-positive, HER2-low, and hormone receptor-positive metastatic breast cancer, evaluating targeted therapies, antibody-drug conjugates, and combination treatment regimens
- Ophthalmology: Participating in clinical trials for neovascular age-related macular degeneration, geographic atrophy, and diabetic retinopathy using innovative drug delivery systems and targeted biologics
- Reproductive Health: Specializing in infertility treatments including ovarian stimulation protocols, luteal phase support optimization, and metabolic interventions to improve IVF outcomes
The center's research portfolio extends to myasthenia gravis, Tourette syndrome, and preventive medicine including meningococcal vaccination studies. With expertise in early-phase through late-stage clinical trials, Hospital Universitari General De Catalunya contributes significantly to the development of breakthrough therapies across diverse medical specialties, maintaining a strong focus on precision medicine approaches in oncology and innovative disease-modifying treatments for neurodegenerative disorders.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 11 therapeutic areas and 15 of 147 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 139 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 20 by active trials.
- 1F. Hoffmann-La Roche AG5active
lock +19 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1F. Hoffmann-La Roche AG10trials
lock +8 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital Universitari General De Catalunya
lock Showing 1 of 73 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (22153) Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | Bayer AG | Phase III | Not Recruiting | Sep 2023 | May 2025 |
IMP list
lock Showing 1 of 147 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Florbetaben (18F) | 4 | Unknown | 2021-10-18 | 2025-11-13 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.